The incidence rate of eye diseases is one of the most prevalent diseases in the world. China has a surprising number of "glasses" in developed countries or developing countries.

In the past, only "laser (corneal) grinding" was used to treat myopia. Besides surgery, myopia patients could only wear glasses to correct diopter. Now, many new types of ophthalmic equipment products are being approved and listed, which brings good news to the majority of myopia and cataract patients.

Researchers from American avedro medical device company are developing a new ophthalmic instrument product, kxl0 system, to treat early myopia. Its working principle is: the use of heat to "iron" the convex cornea, so as to restore its flat state, so as to play a role in correcting myopia.

It is understood that this new myopia therapeutic instrument developed by avedro company has been first listed in European countries in November 2010, and the market response is good. At present, the product has carried out clinical trials in local hospitals in the United States. Once approved by the U.S. FDA, the new product is expected to have annual sales of US $43 million in the future.

Another new product, LASIK (wave front measuring instrument), which can be combined with the existing laser corneal grinding instruments, was developed by researchers from Stanford University in the United States. This product will greatly improve the accuracy of laser grinding of protruding cornea, so as to improve the success rate of myopia correction surgery.

It is reported that the success rate of myopia correction surgery can be increased to 99.9% by using LASIK in combination with the existing laser (corneal) grinder.

And the emergence of ICL (implantable contact keratoprosthesis) technology has given myopic patients a choice. ICL implantation refers to the placement of implantable contact lenses in the eyes with lens to correct vision.

It is understood that ICL is the latest scientific and technological achievement in modern ophthalmic refractive surgery. Its raw material is collagen polymer exclusively produced by Staar company in the United States. It is polymerized by a small amount of purified collagen, which has good biocompatibility and no adverse reactions in the eye.

Compared with other surgical methods, ICL has the advantages of wider range correction of ametropia, better visual effect and no corneal tissue cutting. ICL has been approved by FDA and approved by China food and drug administration to enter the Chinese medical device market.

When it comes to the treatment of cataract, the main treatment of ophthalmologists all over the world is to remove the opaque lens material (cloudiness in the eye) by laser. However, it is difficult to remove the lens opacification, so the effect of operation is easily affected.

Recently, a company in the United States has developed a new device called "nanosecond" auxiliary laser scalpel. It can replace the existing surgical laser scalpel, and more accurately remove the turbid lens tissue, so as to greatly improve the success rate of surgery and effectively restore the normal vision of cataract patients.

To sum up, ophthalmic devices are surgical instruments or therapeutic devices that cover many kinds of ophthalmic diseases. According to the analysis of western market analysts, the total sales volume of ophthalmic devices in the global market has exceeded 20 billion US dollars in 2012, and is still growing steadily.